|1.||Jantová, S: 3 articles (11/2006 - 01/2004)|
|2.||Kyprianou, Natasha: 3 articles (04/2003 - 01/2002)|
|3.||Jin, Yi: 2 articles (07/2013 - 01/2010)|
|4.||Zhang, Yandong: 2 articles (01/2011 - 01/2009)|
|5.||Chen, Zhe: 2 articles (01/2011 - 01/2009)|
|6.||Lou, Yijia: 2 articles (01/2011 - 01/2009)|
|7.||Yu, Yongping: 2 articles (01/2011 - 01/2009)|
|8.||Letasiová, S: 2 articles (11/2006 - 01/2006)|
|9.||Ovádeková, R: 2 articles (11/2006 - 01/2006)|
|10.||Gálvez, Jaime: 1 article (11/2015)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/19/2003 - "The present study provides an initial insight into the molecular targets of the apoptotic action of quinazolines against prostate cancer cells."
04/01/2003 - "Moreover, the apoptotic effect elicited by quinazolines may have high clinical significance in the prevention and treatment of prostate cancer."
03/01/2003 - "This molecular basis of an alpha1-adrenoceptor independent action against prostate cancer cells by the quinazolines may have potential therapeutic significance in prostate cancer."
01/15/2002 - "Transfection-mediated overexpression of alpha1-adrenoceptor in human prostate cancer cells, DU-145 (that lack alpha1-adrenoceptor), did not alter the ability of prostate cancer cells to undergo apoptosis in response to quinazolines. "
01/01/2009 - "A series of 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines were synthesized and evaluated for their cytotoxic activity in vitro against five human cancer cell lines (human lung carcinoma cell line: A549, human leukemia cell lines: K562 and Molt-4, human prostate cancer cell line: PC-3, human breast carcinoma cell line: MDA-MB-231). "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/15/2011 - "This study evaluated the selective effects of 2-isopropyl-3-butyl-8-(4-fluorophenylamino)-3H-imidazo[4,5-g]quinazoline (B-2), a member of a series of quinazolines, on the cell survival and growth of the non-small cell lung cancer (NSCLC) cell line A549 in vitro and in vivo. "
10/01/2015 - "We investigated a group of recently prepared 2-alkyl-substituted quinazolines (2-ASQs) for their antitumor activity against non-small cell lung carcinoma (NSCLC) cells. "
|3.||Breast Neoplasms (Breast Cancer)
11/01/2010 - "A series of novel 8/10-trifluoromethyl-substituted-imidazo[1,2-c] quinazolines have been synthesized and evaluated in vivo (rat paw edema) for their anti-inflammatory activity and in silico (docking studies) to recognize the hypothetical binding motif of the title compounds with the cyclooxygenase isoenzymes (COX-1 and COX-2) employing GOLD (CCDC, 4.0.1 version) software. "
03/01/2012 - "However, the growing knowledge of cancer-related pathways has recently highlighted some novel potential targets for therapy, with quinazolines receiving increasing attention. "
01/01/2010 - "A novel synthetic analog of 5, 8-disubstituted quinazolines blocks mitosis and induces apoptosis of tumor cells by inhibiting microtubule polymerization."
09/01/2009 - "A series of disubstituted 4(3H) quinazolines were designed for potential application in tumors. "
11/01/2006 - "Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. "
01/01/2004 - "Nine substituted tetrazolo[1,5-c]quinazolines have been tested for cytotoxic effects and structure activity relationship on the murine cancer cell line B16 and four bacterial strains. "
|1.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|6.||Phosphodiesterase 5 Inhibitors
|7.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)